Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455059 · ClinicalTrials.gov registry record · Phase 3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
A Phase 3 study of Hypochondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06455059: Active Phase 3 study of Hypochondroplasia, sponsored by BioMarin Pharmaceutical.
NCT06455059 is a Phase 3 study of Hypochondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 80 participants, below the 175-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06455059, a Phase 3 study of Hypochondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vosoritide
Study Locations (20)
Other
- Hospices Civils de Lyon - Hopital Femme Mere Enfant - Lyon
- Hopital de la Timone - Marseille
- Hopital Necker-Enfants Malade - Paris
- CHU de Toulouse - Toulouse
- Uniklinik Koln - Cologne
- Univeristatskinderklinik Magdeburg - Magdeburg
- Instituto Giannina Gaslini - Genoa
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome
- Ospedale Pediatrico Bambino Gesu - Rome
- Osaka University Hosptial - Osaka
- Tokushima University Hospital - Tokushima
- Institute of Science Tokyo Hospital - Tokyo
Delaware
- Nemours Alfred I. DuPont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Wisconsin
- Medical College of Wisconsin - Milwaukee
Victoria
- Murdoch Children's Research Institute - Parkville
Alberta
- University of Alberta Stollery Children's Hospital - Edmonton
Ontario
- SickKids - The Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 3 |
What the registry record for NCT06455059 still lists
NCT06455059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 175-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Hypochondroplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06455059 names 20 study sites across 9 states, led by Other, Delaware, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06455059 about?
NCT06455059 is a clinical study titled "Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia". The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
What is the current status of trial NCT06455059?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2024-06-17. Estimated completion is 2026-08-01.
What conditions does trial NCT06455059 study?
This clinical trial studies the following conditions: Hypochondroplasia.
What interventions are being tested in trial NCT06455059?
The interventions under investigation include: Placebo (DRUG), Vosoritide (DRUG).
Who is sponsoring clinical trial NCT06455059?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455059 being conducted?
This trial has 20 study locations across Delaware, District of Columbia, Illinois, Wisconsin, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypochondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Clinical Assessment Study in Children With Hypochondroplasia
RECRUITING
-
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
RECRUITING · Phase 2
-
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
RECRUITING
-
C-Type Natriuretic Peptide and Achondroplasia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI